Showing results (11-20 of 22) with videos related to
Sort By:
Pageof 3
American Heart Journal|August 2, 2001
The A-to-Z Trial: Methods and rationale for a single trial investigating combined use of low-molecular-weight heparin with the glycoprotein IIb/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapyM A Blazing, J A De Lemos, C K Dyke, et al.Journal of Applied Physiology (Bethesda, Md. : 1985)|November 1, 1995
Effect of skeletal muscle fiber type on the pressor response evoked by static contraction in rabbitsL B Wilson, C K Dyke, D Parsons, et al.The American Journal of Geriatric Cardiology|July 10, 2007
Age-related vascular stiffness and left ventricular size after myocardial infarctionGlenn A Hirsch, W Patricia Ingkanisorn, Steven P Schulman, et al.Journal of the American College of Cardiology|April 4, 2006
Prognosis of negative adenosine stress magnetic resonance in patients presenting to an emergency department with chest painW Patricia Ingkanisorn, Raymond Y Kwong, Nicole S Bohme, et al.JAMA|September 6, 2012
Prevalence and prognosis of unrecognized myocardial infarction determined by cardiac magnetic resonance in older adultsErik B Schelbert, Jie J Cao, Sigurdur Sigurdsson, et al.Circulation|November 15, 2006
First-in-human experience of an antidote-controlled anticoagulant using RNA aptamer technology: a phase 1a pharmacodynamic evaluation of a drug-antidote pair for the controlled regulation of factor IXa activityChristopher K Dyke, Steven R Steinhubl, Neal S Kleiman, et al.JAMA Cardiology|October 11, 2018
Association of Unrecognized Myocardial Infarction With Long-term Outcomes in Community-Dwelling Older Adults: The ICELAND MI StudyTushar Acharya, Thor Aspelund, Torfi F Jonasson, et al.American Heart Journal|February 9, 2002
Misreporting of myocardial infarction end points: results of adjudication by a central clinical events committee in the PARAGON-B trial. Second Platelet IIb/IIIa Antagonist for the Reduction of Acute Coronary Syndrome Events in a Global Organization Network TrialKenneth W Mahaffey, Matthew T Roe, Christopher K Dyke, et al.Circulation|May 22, 2002
First experience with direct factor Xa inhibition in patients with stable coronary disease: a pharmacokinetic and pharmacodynamic evaluationChristopher K Dyke, Richard C Becker, Neal S Kleiman, et al.Journal of Thrombosis and Haemostasis : JTH|March 8, 2005
First experience with direct, selective factor Xa inhibition in patients with non-ST-elevation acute coronary syndromes: results of the XaNADU-ACS TrialJ H Alexander, H Yang, R C Becker, et al.Pageof 3